The business model of Genoway SA revolves around the provision of customized preclinical research models and associated services to the biopharmaceutical industry. As a leading provider in the field of genetically modified laboratory mice, Genoway SA specializes in the design, development, and production of highly specialized animal models that mimic human diseases, aiding researchers in the development of new treatments and therapies. By leveraging their expertise in genetic engineering and molecular biology, Genoway SA offers a range of services such as model creation, breeding, and colony management to facilitate efficient and targeted research.

Genoway SA is primarily active in the biotechnology industry.

The main competitors of Genoway SA in the market include companies such as Charles River Laboratories, Taconic Biosciences, and Transposagen Biopharmaceuticals. These companies also provide services in the field of genetically modified models and related research solutions. However, Genoway SA stands out with its innovative technology and extensive experience in the industry. As a leading provider of custom-made research models and associated services, Genoway SA offers unique solutions tailored to the specific needs of their clients. Their commitment to quality, reliability, and customer satisfaction sets them apart from their competitors in the market.

Genoway SA, a leading company in the field of custom genetically modified mouse models, has an impressive history and background. Founded in 1999, Genoway SA has continuously contributed to the advancement of scientific research through its innovative genomic engineering solutions. With a strong focus on creating efficient research models, the company has established itself as a global leader in the field. Genoway SA's expertise and commitment to excellence have enabled numerous breakthroughs in drug discovery, preclinical evaluation, and therapeutic development. With a dedicated team of experts, Genoway SA consistently strives to provide cutting-edge mouse models that revolutionize the biomedical research community. Trust Genoway SA for your research needs and experience their unparalleled commitment to excellence.

Genoway SA has achieved several significant milestones in its company history. These milestones include successfully establishing itself as a leading provider of customized research models and related services. Additionally, the company has built a strong reputation for its expertise in genetic engineering and the creation of genetically modified animal models. Genoway SA has also expanded its global presence by establishing collaborations and partnerships with renowned academic institutions and industry leaders. These achievements have cemented Genoway SA's position as a key player in the field of genetic research and development, driving innovation and advancements in various scientific disciplines.

Genoway SA is primarily present in Europe, with a strong presence in France. As a leading biotechnology company, Genoway SA operates globally with a focus on providing innovative animal models and research services. Their extensive network and collaborations span across various regions, including Europe, North America, and Asia. With their commitment to research and development, Genoway SA continues to expand its presence internationally, delivering cutting-edge solutions to clients worldwide.

Genoway SA is a leading company that represents values and a corporate philosophy centered around innovation, collaboration, and scientific expertise. With a strong focus on providing cutting-edge solutions in the field of genetically modified organisms (GMOs) for the pharmaceutical and biotechnology industries, Genoway SA aims to revolutionize drug discovery and development. Their commitment to excellence, integrity, and sustainability is reflected in every aspect of their operations. By leveraging advanced gene editing technologies and a multidisciplinary approach, Genoway SA strives to contribute to the advancement of life science research and to address critical healthcare challenges globally.

Analysts currently set an average price target of 6.02 EUR for the Genoway stock (median: 6.02 EUR), implying +157.2 % versus the latest price. The consensus is based on 9 analyst ratings.

Genoway Analyst Price Targets 2026

9 analysts currently rate the Genoway stock: 8 recommend buying, 1 holding and 0 selling.

Genoway Analyst Price Targets 2026

The Genoway share (ALGEN.PA) is listed on 4 stock exchanges, including: Frankfurt (JEH.F), München (JEH.MU), Paris (ALGEN.PA).

Genoway SA is a leading biotech company based in Lyon, France, specializing in the development and sale of genetically modified animal models for biomedical research. The company offers customized genetic services to academic and industrial customers and is known for its expertise and innovation in its offerings. Genoway specializes in the production of transgenic and knockout mouse models using gene editing technologies such as CRISPR/Cas9 to selectively modify or disable specific genes. The products and services of Genoway include the delivery of fully customized animal models for research. The company offers a variety of product lines tailored to specific research needs, such as oncology, immunology, and neurology. The various product lines of Genoway include genetically modified mice, rats, and rabbits. Mice are the most commonly used animals for medical research, and the company specializes in developing models for cancer, inflammation, autoimmune diseases, and infectious diseases. Genoway's products offer numerous benefits by simulating the phenotypic effect of gene mutations observed in many human diseases. This allows scientists to study the effects of drugs, therapies, and other interventions on these specific diseases. In addition, genetically modified animals reduce the extent of animal research, contributing to the optimization of research outcomes. The company has also developed a specialized analysis service concept that allows researchers to quickly and easily test their genetically modified animal models for gene mutations responsible for the desired disease characteristics. Genoway has also gained a high level of recognition through its collaborations with various research institutions and pharmaceutical companies. This has enabled the company to position itself as a leading provider of customized genetic services in the biotech industry. In summary, Genoway's business model aims to meet the needs of customers in the biotech industry by offering a wide range of customized products and services. By utilizing gene editing technologies and focusing on specific animal models for medical research, the company has developed innovative and high-quality solutions that are widely adopted and accepted in the biotech industry.

The expected revenue of Genoway is 26.27 M EUR. This figure is based on current financial data and reflects the company's business performance.

The profit cannot currently be calculated for Genoway.

The P/E ratio cannot be calculated for Genoway at the moment.

The price-to-sales ratio (P/S) of Genoway is currently 0.79. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Genoway stock.

The Eulerpool Quality Score for Genoway is 5/10.

The ISIN of Genoway is FR0004053510. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Genoway is A0MRJ4. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Genoway is ALGEN.PA. The ticker symbol is used to trade Genoway shares on the stock exchange.

Genoway paid dividends every year for the past 0 years.

Genoway is assigned to the 'Health' sector.

The dividends of Genoway are distributed in EUR.